CD274 and neoplasm: For example, in the context of chemotherapy-refractory or locally advanced mCRC, the combination of cobimetinib, a mitogen-activated protein kinase kinase (MEK) inhibitor with atezolizumab (an anti-PD-L1 checkpoint inhibitor) has so far displayed potentiation for anti-tumor T-cells to yield durable and improved OS, compared to those reported with standard of care regimes, with an acceptable safety profile [69].